Evosep Webinar
Advancing Plasma Proteomics
September 24, 2026 I 16:00 PM CEST / 10:00 AM EDT / 07:00 AM PST
Plasma proteomics offers significant opportunities for biomarker discovery, disease research, and the development of new approaches to precision medicine. However, translating these opportunities into large-scale studies requires robust, reproducible, and scalable workflows.
In this webinar, our speakers will share their perspectives on advances in plasma proteomics and explore how modern proteomics workflows are enabling researchers to analyze larger sample cohorts while generating consistent, high-quality data.
High-Throughput Plasma Proteomics Reveals Insights into Pancreatic Cancer Biology
Talk by Sindisiwe Buthelezi, Senior Researcher at the Council for Scientific and Industrial Research (CSIR), South Africa
Extracellular vesicles carry a wealth of biologically relevant proteins that can provide a window into disease processes. In this webinar, Sindisiwe Buthelezi will discuss how extracellular vesicle-enriched plasma proteomics was used to uncover molecular signatures associated with pancreatic ductal adenocarcinoma in a South African patient cohort. Using the Mag-Net workflow and Evosep One-enabled LC-MS analysis, the team identified proteins linked to tumor progression, inflammation, and disease severity, demonstrating the power of standardized, high-throughput proteomics for biomarker discovery and translational cancer research.
Untangling the Clinical Heterogeneity in Rare Blood Cancer by mass spectrometry-based plasma proteomics
Talk by Pieter Langerhorst, Junior Group Leader at Sanquin, The Netherlands
Rare hematological malignancies often present with diverse clinical trajectories that are difficult to predict using conventional biomarkers alone. In this webinar, Pieter Langerhorst will showcase how mass spectrometry-based plasma proteomics can reveal biological differences underlying disease heterogeneity, enabling improved patient stratification and the discovery of novel biomarkers. The findings demonstrate the value of high-throughput plasma proteomics as a tool for translational research and precision medicine.
